Trial site
Koranyi National Institute For Pulmonology
- 21running trials
- 19closed trials
The trials here
What the 40 trials at this site are about, from their registry records.
- Conditions
- Lung cancer35 trials
- Idiopathic pulmonary fibrosis3 trials
- COPD1 trial
- Systemic sclerosis (scleroderma)1 trial
- Phase
- Phase 327 trials
- Phase 211 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Completed18 trials
- Active, not recruiting13 trials
- Recruiting8 trials
- Withdrawn1 trial
- Lead sponsor
- Merck Sharp & Dohme LLC11 trials
- AstraZeneca6 trials
- Amgen3 trials
- Boehringer Ingelheim2 trials
- Daiichi Sankyo2 trials
- and 16 more
Running trials
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer7 recruiting
Closed trials
Completed
Completed
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Active, not recruiting
Active, not recruiting
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Active, not recruiting
Completed
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Active, not recruiting
Active, not recruiting
Completed
Completed
Completed
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003)
Completed
Active, not recruiting
Completed
Recruiting
Completed
Completed
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC
Site data: EU CTIS (euclinicaltrials.eu)Updated 19 Nov 2026